Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

XBRL 30 June 2022 filed with the SEC

September 1, 2022May 23, 2023 Alterity Therapeutics

XBRL 30 June 2022 filed with the SEC

2022

Post navigation

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe

Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy

Related Posts

Alterity in the news: Herald Sun

May 27, 2019August 16, 2022

Prana Doses First Patient in the “IMAGINE” Phase II Alzheimer’s Disease Trial

July 17, 2013August 16, 2022

Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases

November 16, 2020August 16, 2022

Recent Posts

Alterity Therapeutics Prominently Featured at the International MSA Congress
Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
Appendix 4C – Q3 FY25 Quarterly Cash Flow Report
Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065